Drug Database
VO

voglibose + mitiglinide (Glubes)

✓ Approved

Takeda · GAA · Small Molecule

What is voglibose + mitiglinide?

voglibose + mitiglinide is a small molecule developed by Takeda. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesGlubes
CompanyTakeda
Drug ClassSmall Molecule
Molecular TargetGAA, KCNJ11, ABCC8
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Takeda

Mechanism of Action

Molecular Targets

voglibose + mitiglinide acts on 3 molecular targets:

GAAglucosidase alpha, acid (LYAG)
KCNJ11potassium inwardly rectifying channel subfamily J member 11 (BIR, HHF2)
ABCC8ATP binding cassette subfamily C member 8 (MRP8, SUR1delta2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

voglibose + mitiglinide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

Related Research Articles

PubMedMini reviews in medicinal chemistry2026-11-05

Click Chemistry in the Design of 1,2,3-Triazole based α-Glucosidase Inhibitors: Emerging Trends and SAR Insights for Type 2 Diabetes Mellitus.

Rahman Md Fazlur MF, Alam Ozair O, Jha Mukund M, Mathur Vishal V et al.

Type 2 diabetes mellitus (T2DM) poses a widespread challenge to public health across the globe, necessitating the development of safer and more effective therapeutic agents. α- glucosidase has emerged as an important therapeutic target due to its role in delaying carbohydrate digestion and controlling postprandial glucose levels; its inhibition slows glucose absorption in the small intestine, effectively helping to manage postprandial hyperglycemia. Existing α-glucosidase inhibitors such as acarbose, miglitol, and voglibose are constrained by gastrointestinal side effects and limited efficacy. These drawbacks, along with complex synthesis, have directed current research toward designing simpler heterocyclic scaffolds as potential α-glucosidase inhibitors. Click chemistry offers a versatile and efficient synthetic approach based on simple, reliable reactions. Recent advances in medicinal chemistry highlight 1,2,3-triazole scaffolds derived from click chemistry as promising frameworks for designing novel α-glucosidase inhibitors with enhanced bioactivity. This review evaluates 1,2,3-triazole-based compounds developed between 2019 and 2025 for their inhibitory potential. A wide spectrum of triazole-linked hybrids, including quinoline, coumarin, xanthone, and benzimidazole, is examined with a focus on their synthesis, in vitro potency, and structureactivity relationship analyses. The findings emphasize how specific substituents, such as halogen and electron-withdrawing groups, could modulate biological activity. Furthermore, challenges in development, including protein/receptor specificity, synthetic complexity, and side effects of α- glucosidase inhibitors, are discussed alongside future directions for the rational design of more efficacious and target-specific inhibitors. This work consolidates recent progress and underscores the potential of 1,2,3-triazole derivatives as an effective motif in the ongoing quest for improvement of antidiabetic therapeutics.

PMID 42983263
Read full article →
PubMedThe Journal of international medical research2026-11-03

Clopidogrel-induced insulin autoimmune syndrome: A case report and analysis of clinical characteristics in Chinese patients.

Liu Haoyue H, Wang Jing J, Wang Yingying Y, Han Wenxue W et al.

Clopidogrel-induced insulin autoimmune syndrome is a rare condition that typically presents with hypoglycemic symptoms, making clinical recognition challenging and often leading to misdiagnosis or underrecognition as a drug-related adverse event. Systematic analyses of clopidogrel-induced insulin autoimmune syndrome in the Chinese population remain limited. This report describes a 69-year-old Chinese man who developed insulin autoimmune syndrome following clopidogrel administration. His condition improved after clopidogrel discontinuation, switching to ticagrelor, dietary modification, and treatment with voglibose. Additionally, published cases of clopidogrel-associated insulin autoimmune syndrome in the Chinese population were systematically retrieved from PubMed, Embase, the China National Knowledge Infrastructure, and Wanfang databases up to October 2025. The clinical characteristics of clopidogrel-associated insulin autoimmune syndrome in the Chinese population were summarized. Cases involving patients from other countries were also included for comparison to identify similarities and differences in disease characteristics between Chinese and non-Chinese populations. This study aimed to provide a reference for the early clinical recognition and individualized diagnosis and treatment of this condition.

PMID 42975052
Read full article →
PubMedMini reviews in medicinal chemistry2026-10-09

Exploring Isatin Derivatives as Multifunctional Antidiabetic Agents: Insights into α-Glucosidase and α-Amylase Inhibition.

Sardar Manami M, Chakraborty Teasha T, Mondal Prasenjit P, Das Priya P

Diabetes mellitus, especially Type 2 Diabetes (T2DM), appears to be a worldwide health challenge marked by progressing hyperglycemia and related complications. Postprandial Hyperglycemia (PPHG) is a critical therapeutic target due to its strong link with cardiovascular risks. Inhibition of carbohydrate-hydrolysing enzymes, α-glucosidase and α-amylase, is an established strategy to mitigate PPHG. Current Inhibitors, including acarbose, miglitol, and voglibose, are effective but limited by gastrointestinal side effects. Isatin (1H-indole-2,3-dione) is a privileged scaffold in medicinal chemistry with diverse biological activities and modifiable sites (N-1, C-3, C-5), enabling optimisation for enzyme inhibition. A comprehensive literature search was conducted up to December 2025 using databases including Google Scholar, Web of Science, PubMed, traditional integrated knowledge resources, local dissertations, and books. The search employed keywords such as "α- glucosidase," "type 2 diabetes," "isatin scaffolds," "standard α-glucosidase enzyme inhibitors," and "isatin derivatives showing α-glucosidase and α-amylase inhibitory activity." This review compiles recent advances in isatin derivatives as potential α-glucosidase and α-amylase inhibitors, highlighting structure-activity relationships, synthetic strategies, including green chemistry and microwaveassisted synthesis, and dual inhibitory activity for improved efficacy and safety. Reported derivatives demonstrate remarkable potency, with some surpassing standard drugs in IC₅₀ values and docking scores, offering promising leads for next-generation antidiabetic therapeutics. Isatin derivatives show strong potential as multifunctional antidiabetic agents by effectively inhibiting α- glucosidase and α-amylase. Their structural versatility enables enhanced enzyme inhibition, supporting their promise as lead compounds for postprandial glucose control.

PMID 42852753
Read full article →
PubMedMini reviews in medicinal chemistry2026-09-15

Oxadiazole-based Inhibitors Targeting Carbohydrate-Hydrolyzing Enzymes in Type 2 Diabetes Mellitus: Synthetic Strategies, Structure- Activity Relationships, and Translational Perspectives.

Sharma Shivank S, Kumar Shubham S, Wadhwa Pankaj P

Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder characterized by insulin resistance, progressive β-cell dysfunction, and chronic hyperglycemia, leading to microvascular and macrovascular complications. Among current therapeutic strategies, inhibition of intestinal carbohydrate-hydrolyzing enzymes, namely α-amylase and α-glucosidase, represents an established approach for controlling postprandial glucose excursions. However, clinically used inhibitors such as acarbose, miglitol, and voglibose are associated with gastrointestinal intolerance, limited selectivity, and variable efficacy, highlighting the need for improved therapeutic agents. In this context, 1,3,4-oxadiazole-based scaffolds have emerged as promising pharmacophores in antidiabetic drug design. The 1,3,4-oxadiazole ring acts as a bioisostere of amide and ester functionalities, conferring favorable physicochemical properties including enhanced metabolic stability, lipophilicity, and hydrogen-bonding capability. Structure-activity relationship (SAR) studies reported between 2015 and 2025 demonstrate that substituent effects-particularly phenolic hydroxyl groups, halogenation patterns, and extended aromatic systems-play a critical role in optimizing enzyme inhibition through hydrogen bonding, hydrophobic interactions, and π-π stacking within catalytic sites. While several oxadiazole-based hybrids incorporating privileged scaffolds such as benzimidazole, coumarin, and thiazolidinedione have been explored, evidence supporting modulation of additional targets including protein tyrosine phosphatase 1B (PTP1B), aldose reductase (ALR2), and inflammatory pathways such as the NLRP3 inflammasome remains limited and primarily derived from in vitro or computational studies. Computational approaches, including molecular docking, 3D-QSAR, and molecular dynamics simulations, have supported the rational optimization of oxadiazole derivatives, although their predictive limitations should be acknowledged. Despite encouraging preclinical findings, clinical translation remains constrained by insufficient pharmacokinetic, toxicological, and long-term efficacy data. Future research should prioritize systematic ADMET evaluation, standardized biological validation, and mechanistic expansion beyond carbohydrase inhibition to enable the development of clinically viable oxadiazole-based antidiabetic agents.

PMID 42736664
Read full article →
PubMedEndocrine connections2026-09-07

Post-bariatric hypoglycaemia: an under-recognized complication of weight loss surgery - a case series.

Tatachar Sreevatsa S, Agarwal Khushboo K, Paravathareddy Sandhiya S, Jiwanmall Stephen S et al.

Post-bariatric hypoglycaemia (PBH) has emerged as a significant, under-recognized complication following Roux-en-Y gastric bypass (RYGB) and other weight loss surgeries. The purpose of this study was to characterize the timing, clinical presentation, diagnosis and management outcomes of PBH in a diverse case series from a multi-speciality centre in Southern India owing to a predominantly high-carbohydrate diet and distinct bariatric phenotype. This was a retrospective observational case series analysis from a multidisciplinary bariatric clinic at a tertiary teaching hospital in Southern India from May 2017 to April 2024. Time to onset of PBH, nadir plasma glucose levels, management approach (diet, medication and surgery), complication rates and patient follow-up duration were evaluated. Nine adults (mean age: 41.5 years; both sexes) were diagnosed and managed for PBH following RYGB. PBH onset ranged from 1 month to 5 years following RYGB (mean: 17 months). Nadir glucose levels ranged from 16 to 67 mg/dL. Hyperinsulinaemia and nesidioblastosis were diagnosed in select cases. Patients received individualized medical nutrition therapy, medication (voglibose, octreotide and diazoxide) and, in severe/refractory cases, surgical procedures such as reversal of RYGB or subtotal pancreatectomy, as was required in two patients. Frequent and severe PBH episodes were more common in patients with higher initial BMI and persistent carbohydrate-heavy diet intake. PBH after bariatric surgery presents with variable onset, severity and duration, emphasizing the need for long-term multidisciplinary follow-up and individualized management, especially for high-risk populations. Early recognition and tailored intervention can improve clinical outcomes and patients' quality of life.

PMID 42703785
Read full article →
PubMedCureus2026-08-28

A Comparative Study to Evaluate the Renoprotective Effect of Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus.

Pichholiya Meenu M, Abhinav Raj R, Singh Sakshi S, Yadav Arvind K AK et al.

Type 2 diabetes mellitus (T2DM) is a metabolic condition that often leads to long-term microvascular and macrovascular complications. Among its most frequent and severe complications is diabetic nephropathy, which stands as a primary contributor to chronic kidney disease and end-stage renal disease on a global scale. Literature search studies have exhibited both renoprotective and non-renoprotective effects of different antidiabetic drugs, and to our knowledge, no study comparing the renoprotective effect of antidiabetic drugs was found, so this study was designed to assess the impact of these drugs on kidney function in patients with T2DM. A prospective observational study was carried out on 100 patients with T2DM at a tertiary care hospital after approval from the institutional ethics committee. Informed consent was obtained from all patients. Patients aged ≥18 years receiving antidiabetic therapy were included in the study. Data, including demographic details, ongoing antidiabetic treatment, and clinical parameters, were recorded and analyzed according to the prescribed drug therapy. Glycemic control was assessed using HbA1c levels, while renal function was evaluated using renal parameters at baseline and during follow-up visits. The data was analyzed using IBM SPSS Statistics for Windows, Version 20 (Released 2011; IBM Corp., Armonk, New York, United States). A student's t-test and ANOVA were applied as appropriate, and a p-value < 0.05 was considered statistically significant. Patients receiving metformin and gliptin therapy showed a statistically significant reduction (p < 0.05) in HbA1c levels and mean serum urea during the study period. Serum creatinine levels were found to be slightly higher than the normal range in all the groups except metformin-based combination therapy with sulfonylureas and metformin-based combination therapy with sulfonylureas plus voglibose at the first visit. The values dropped down gradually in subsequent visits in all the groups except in the insulin group and the metformin-with-voglibose group, but were not statistically significant. A significant reduction was observed in the group taking metformin with sodium-glucose cotransporter 2 (SGLT2) inhibitors and gliptins. Renal function tests, such as serum urea and serum creatinine levels, showed significant changes during all three subsequent follow-ups. Proper use of antidiabetic drugs, particularly oral combination therapy, not only improves blood sugar control but also helps in protecting kidney function in diabetic patients. Future investigations with large sample sizes and longer observation periods are warranted to substantiate these findings.

PMID 42662112
Read full article →

+498 more articles available with a free account

Sign up free to view all articles →

Ask about voglibose + mitiglinide